PARP Inhibitor Applicability: Detailed Assays for Homologous Recombination Repair Pathway Components

Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes ever mor...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2022-01, Vol.15, p.165-180
Main Authors: O'Sullivan Coyne, Geraldine, Karlovich, Chris, Wilsker, Deborah, Voth, Andrea Regier, Parchment, Ralph E, Chen, Alice P, Doroshow, James H
Format: Article
Language:English
Subjects:
Biological products
Biotechnology
Cancer
Care and treatment
DNA damage
DNA repair
Genetic research
Molecular biology
Monoclonal antibodies
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Poly(ADP-ribose) polymerase inhibitors (PARPi) have been in clinical use since 2014 for certain patients with germline mutations, but as evidence and approvals for their use in a wider range of patients grow, the question of how best to identify patients who would benefit from PARPi becomes ever more complex. Here, we discuss the development and current state of approved selection testing for PARPi therapy and the ongoing efforts to define a broader range of homologous recombination repair deficiencies that are susceptible to PARP inhibition.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S278092